IRVINE, CA--(MARKET WIRE)--Sep 22, 2008 -- BIOLASE Technology, Inc. (BLTI - News), the world's leading dental laser company, announced today that it was recently granted a Japanese method and apparatus patent (Patent Number 4073036) with a total of 63 claims related to the use of lasers with water particles to cut and treat various types of tissue, hard or soft, for a variety of dental and medical applications.

"While we have had a number of recent successes in laser and consumable patents and global product launches, this is our first Japanese patent for Waterlase MD technology and applications," said Chief Executive Officer Jake St. Philip. "To date Waterlase® has made its initial entry into more than 50 countries. Gaining approval to sell Waterlase in Japan is a key part of a more focused and profitable expansion strategy into key international markets. In the coming months, we look forward to finalizing and sharing a number of other international initiatives."

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, develops, manufactures and markets lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

     For further information, please contact:
     David Mulder
     Chief Financial Officer
     BIOLASE Technology, Inc.
     +1-949-361-1200
      
     Jill Bertotti
     Allen & Caron
     +1-949-474-4300